Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty breathing, wheezing, and coughing. It affects millions of people worldwide, and is the leading cause of chronic illness in children. Despite advances in medication and treatments, asthma continues to be a difficult condition to manage, and many sufferers are desperate for new hope. Fortunately, a new treatment known as Bronchial Thermoplasty (BT) is offering hope to those with severe, persistent asthma. BT is a minimally invasive procedure designed to reduce the severity of asthma symptoms. It involves using a special device to heat the airways, which reduces the amount of smooth muscle tissue and decreases the severity of asthma attacks.
Bronchial Thermoplasty is an innovative treatment for severe, persistent asthma. It is a minimally invasive procedure that involves using a special device to heat the airways, which reduces the amount of smooth muscle tissue and decreases the severity of asthma attacks. The procedure is performed in a hospital, and typically takes about an hour. The procedure works by heating the airways, which causes the smooth muscle tissue to shrink. This helps reduce the severity of asthma symptoms, such as coughing, wheezing, and difficulty breathing. The procedure is relatively safe, and the side effects are usually mild.
Bronchial Thermoplasty has several benefits for asthma sufferers. First, it can reduce the severity of asthma attacks, which can help reduce the frequency of hospital visits. Second, it can reduce the need for medication, as the procedure can reduce the severity of symptoms. Third, it can reduce the risk of complications from asthma, such as pneumonia. Finally, it can improve quality of life for those with severe, persistent asthma.
Bronchial Thermoplasty is typically recommended for those with severe, persistent asthma who have not responded to other treatments. In general, those who are 18 years or older and have had asthma for at least two years are considered to be good candidates for the procedure.
Although Bronchial Thermoplasty is a safe and effective treatment for severe, persistent asthma, there are some risks and side effects associated with the procedure. These include sore throat, chest pain, and coughing. In rare cases, there can be more serious side effects, such as pneumothorax (collapsed lung) or bronchospasm (narrowing of the airways).
Bronchial Thermoplasty is a promising new treatment for those with severe, persistent asthma. It is a minimally invasive procedure that can reduce the severity of asthma symptoms, as well as reduce the need for medication and the risk of complications. Although there are some risks and side effects associated with the procedure, it is generally considered to be safe and effective. For those with severe, persistent asthma, Bronchial Thermoplasty offers new hope.
1.
FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma
2.
The Early Progression of Prostate Cancer Is Not Stopped by Metformin.
3.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.
1.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
2.
Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication
3.
Understanding Iron Saturation Levels in Your Blood
4.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
5.
Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation